Atara生物医药 ATRA 深 沪
已收盘 08-01 16:00:00 美东时间
11.55
+0.030
+0.26%
华盛通- 最 高11.73
- 今 开11.40
- 成交量 3.98万股
- 最 低 10.92
- 昨 收 11.52
- 总市值 7848.92万
- 52周最高 18.705
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.005
- 委 比 -88.43%
- 总股本 679.56万
- 历史最高 1639.00
- 量 比 0.64
- 振 幅 7.03%
- 历史最低 4.965
- 每 手 1
- 风险率 6.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多生产经营｜绿色船舶+1 广船国际交付4.95万吨甲醇双燃料油轮
7月22日，中船集团广船国际联合中船贸易为丹麦HAFNIA和法国SOCATRA创立的合资公司ECOMAR建造的4.95万吨甲醇双燃料油轮3号船“ECOMAR ...
07-25 17:16
Atara Biotherapeutics Says FDA Accepts Filing Of BLA For Tabelecleucel Indicated As Monotherapy For Treatment Of Patients With EBV+ PTLD Who Have Received At Least One Prior Therapy
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLDAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell
07-24 20:20
Atara gains after insider purchase
Shares of Atara Biotherapeutics (NASDAQ:ATRA) spiked for the second straight session on Tuesday following an insider purchase of more than 19K company shares by Panacea Innovation Ltd., an investor wi...
07-23 03:02
Pierre Fabre Pharma Announces Transfer Of IND Application For Tabelecleucel From Its Partner, Atara Biotherapeutics
Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical programEnrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating
07-15 20:19
Zura Bio appoints Eric Hyllengren as CFO
Zura Bio (NASDAQ:ZURA) has announced the appointment of Eric Hyllengren as CFO, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as...
07-01 19:44
Atara Biotherapeutics Holds Annual Stockholders Meeting
Atara Biotherapeutics ( ($ATRA) ) has provided an update. On June 10, 2025, Ata...
06-12 04:57
Atara Biotherapeutics Announces $16M Stock Offering
Atara Biotherapeutics ( ($ATRA) ) has shared an announcement. On May 14, 2024, ...
05-17 05:48
Atara Biotherapeutics Q1 EPS $3.50 Beats $(1.98) Estimate, Sales $98.15M Beat $5.67M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $(1.98) by 276.77 percent. This is a 160.87 percent increase over losses of $(5.75) per
05-15 21:17
Atara Biotherapeutics Appoints New Board Members Amid Restructuring
Atara Biotherapeutics ( ($ATRA) ) has shared an update. On May 14, 2025, Atara ...
05-15 20:57
Atara Biotherapeutics prices $16M public offering
Atara Biotherapeutics (NASDAQ:ATRA) announced the pricing of an offering of 834,237 shares of common stock at $6.61/share and pre-funded warrants to purchase 1.59M shares of common stock at $6.6099/pr...
05-15 20:42
